Literature DB >> 30206043

Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System.

Zoe Wainer1, Gavin M Wright2, Karla Gough3, Marissa G Daniels4, Prudence A Russell5, Peter Choong6, Matthew Conron7, David Ball8, Benjamin Solomon9.   

Abstract

INTRODUCTION: Non-small-cell lung cancer (NSCLC) has disproportionately negative outcomes in men compared with women. The importance of the relationship between sex and tumor, node, metastases (TNM) staging system remains unknown. The objective of this study was to investigate the effect of sex on NSCLC survival for each stage in the eighth edition of the TNM staging system in NSCLC. PATIENTS AND METHODS: Two cohorts treated surgically with curative intent between 2000 and 2010 were analyzed. The primary cohort was from Australia with a second population set from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analyses of putative and validated prognostic factors were undertaken to investigate sex-dependent prognostication with detailed analyses of sex differences in each TNM stage. The primary outcome was disease-specific survival (DSS) at 5 years.
RESULTS: Inclusion criteria were met by 555 patients in the Australian cohort, 335 men (60.4%) and 220 (39.6%) women; and 47,706 patients from the SEER cohort, 24,671 men (51.7%) and 23,035 women (48.3%). Five-year DSS was significantly worse for men in multivariate analyses for the Australian (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.04-1.98; P = .026) and SEER (HR, 1.24; 95% CI, 1.20-1.28; P < .001) cohorts. Detailed analysis of TNM stage sex differences revealed a consistent pattern of men having worse survival than women across stages in both cohorts.
CONCLUSION: The poorer survival in men with NSCLC presents research and clinical communities with an important challenge. This study's findings suggest that for men and women diagnosed with NSCLC, and managed surgically, stage-specific outcomes should be quoted separately and consideration to a rapid prognostic score with sex combined with staging as a key element.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gender; Lung cancer; Surgical oncology; Thoracic surgery; Tumor staging

Mesh:

Year:  2018        PMID: 30206043     DOI: 10.1016/j.cllc.2018.08.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  11 in total

Review 1.  Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Authors:  Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field
Journal:  Nat Rev Clin Oncol       Date:  2020-10-12       Impact factor: 66.675

Review 2.  Sex Differences in Cancer Genomes: Much Learned, More Unknown.

Authors:  Chenghao Zhu; Paul C Boutros
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

3.  Enlarged Mediastinal Lymph Nodes in Computed Tomography are a Valuable Prognostic Factor in Non-Small Cell Lung Cancer Patients with Pathologically Negative Lymph Nodes.

Authors:  Yuansheng Zheng; Yiwei Huang; Guoshu Bi; Zhencong Chen; Tao Lu; Songtao Xu; Cheng Zhan; Qun Wang
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

4.  CORR Insights®: Patterns of Change Over Time in Knee Bone Shape Are Associated with Sex.

Authors:  Peter F M Choong
Journal:  Clin Orthop Relat Res       Date:  2020-07       Impact factor: 4.755

Review 5.  Lung cancer in women in 21th century.

Authors:  Joanna Domagala-Kulawik; Anna Trojnar
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

6.  Sex and survival in non-small cell lung cancer: A nationwide cohort study.

Authors:  Cecilia Radkiewicz; Paul William Dickman; Anna Louise Viktoria Johansson; Gunnar Wagenius; Gustaf Edgren; Mats Lambe
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

7.  Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.

Authors:  Chao Tu; Yingqi Pi; Shan Xing; Yang Ling
Journal:  PLoS One       Date:  2020-10-19       Impact factor: 3.240

Review 8.  Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.

Authors:  Ana Casal-Mouriño; Alberto Ruano-Ravina; María Lorenzo-González; Ángeles Rodríguez-Martínez; Alexandra Giraldo-Osorio; Leonor Varela-Lema; Tara Pereiro-Brea; Juan Miguel Barros-Dios; Luis Valdés-Cuadrado; Mónica Pérez-Ríos
Journal:  Transl Lung Cancer Res       Date:  2021-01

9.  BHLHE41/DEC2 Expression Induces Autophagic Cell Death in Lung Cancer Cells and Is Associated with Favorable Prognosis for Patients with Lung Adenocarcinoma.

Authors:  Toshiyuki Nagata; Kentaro Minami; Masatatsu Yamamoto; Tsubasa Hiraki; Masashi Idogawa; Katsumi Fujimoto; Shun Kageyama; Kazuhiro Tabata; Kohichi Kawahara; Kazuhiro Ueda; Ryuji Ikeda; Yukio Kato; Masaaki Komatsu; Akihide Tanimoto; Tatsuhiko Furukawa; Masami Sato
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

10.  TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.

Authors:  Donald Freudenstein; Cassandra Litchfield; Franco Caramia; Gavin Wright; Benjamin J Solomon; David Ball; Simon P Keam; Paul Neeson; Ygal Haupt; Sue Haupt
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.